数据显示，截至2026年1月30日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、迈瑞医疗、恒瑞医药、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.9%。 截至2026年2月10日 10:28，中证医药及医疗器械创新指数(931484)上涨0.50%，成分股海思科上涨 3.59%，药明康德上涨2.11%，康龙化成上涨1.76%，惠泰医疗上涨1.75%，兴齐眼药上涨1.66%。医疗创 新ETF(516820)上涨0.27%，最新价报0.37元。 消息面上，韩国一家数字医疗初创企业9日说，已开发出一款基于人工智能(AI)的数字诊断平台，可以 帮助人们在家尽早发现心脏病发作的先兆。 平安证券指出，2026年设备更新政策持续加码，叠加紧密型县域医共体建设与强基工程推进，基层医疗 设备规模化采购空间打开；国产头部企业如迈瑞医疗、联影医疗、开立医疗招投标金额同比分别增长 36%、34%、77%，行业向上拐点趋势明确。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备 ...

Group 1 - The Hong Kong pharmaceutical outsourcing sector experienced a strong rally on February 10, with several companies seeing significant stock price increases [1] - Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rose by over 3% [1] - Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) each saw their stock prices increase by more than 2.5% [1]

Group 1 - The Hong Kong pharmaceutical outsourcing sector has shown strong fluctuations, with companies such as Zhaoyan New Drug (06127.HK), WuXi Biologics (02269.HK), and Via Biotechnology (01873.HK) all rising over 3% [1] - Other companies like Tigermed (03347.HK), WuXi AppTec (02359.HK), and Kelun Pharmaceutical (06821.HK) have also experienced increases of more than 2.5% [1]

Group 1: Key Insights on the Machine Dog Industry - The quadruped robot industry is experiencing rapid application expansion, with strong environmental adaptability and commercial viability [4][12] - Key application scenarios include defense, industrial inspection, emergency rescue, and consumer household use, indicating a promising long-term market potential [4][12] - Domestic brands dominate the market, with over 50 companies actively participating, including notable players like Yushutech and Boston Dynamics [4][12] Group 2: Insights on the Power Generation Sector - In the thermal power sector, both coal and electricity prices are declining, leading to improved profit margins for coal-fired power plants [4][12] - Hydropower utilization hours are expected to increase due to favorable water conditions, with a projected utilization of 3367 hours in 2025, up 12 hours year-on-year [4][12] - Nuclear power is maintaining a high approval rate, with 10 new units expected to be approved in 2025, although profitability may be impacted by declining market electricity prices [4][12] Group 3: Recommendations for Investment - For thermal power, recommended companies include Guodian Power and Inner Mongolia Huadian, which benefit from stable profit margins [5][12] - In hydropower, companies like Yangtze Power and State Power Investment are highlighted for their potential growth due to improved financial conditions [5][12] - In the natural gas sector, companies such as Kunlun Energy and New Hope Energy are recommended due to expected profitability improvements from cost reductions [5][12]

A股这7大板块，勾勒出中 国经济全貌 出品 | 妙投APP 作者 | 妙投团队 编辑 | 丁萍 头图 | AI制图 幸福的人大致相同，不幸的人各有各的不幸。 银河证券研报显示，截至1月31日，2956家A股上市公司已披露2025年年报业绩预告，披露率为54%。其中 电机、地面兵装、个护用品、风电设备预喜率 （包括扭亏、续盈、略增、预增等情形） 超过70%，汽车行 业超过50%，受益于AI算力需求的电子和通信行业，预喜率分别达到45%和37%。这些大体上属于科技、高 端制造、新消费等领域。 而传统行业，大多较为一般。 煤炭、房地产、轻工制造、建筑装饰、食品饮料、社会服务、石油石化等行业预喜率较低，均低于25%； 焦炭、体育、林业、农业综合、厨卫电器、油气开采、白酒行业预喜率更是均为0%；传统行业中预喜率较 高的，主要是非银金融、有色金属、钢铁、公用事业等少数行业。 展望2026年，有些业绩不错的行业，有望继续保持成长。而有些2025年经营惨淡的行业，也有边际复苏的 机会，或者有复苏的预期。 这句话放到宏观经济各个层面中来看，也是如此。有的行业经历着良好的增长，有的行业在期待着复苏的 曙光。 2025年到现在，无 ...

Group 1 - The CXO sector experienced a notable rebound in early 2026, primarily driven by domestic demand-focused CRO and experimental service companies, while leading CDMO companies with significant global exposure underperformed [2][25] - The current market activity reflects a short-term rebound rather than a comprehensive recovery of the CXO industry, with investors favoring easily confirmable segments [2][25] Group 2 - After a low in 2024, domestic innovative drug financing has improved, with policy expectations and order stability more evident in companies focused on domestic demand, while external demand CDMOs face a more complex pricing environment [4][27] - Despite overall industry sentiment improving, the market remains cautious towards CDMOs, which are seen as having the most certain fundamental recovery and highest order visibility [4][27] Group 3 - WuXi AppTec's 2025 performance forecast indicates a projected revenue of approximately 45.46 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 19.15 billion RMB, reflecting a significant growth of 102.65% [6][30] - The company's revenue guidance was adjusted upward multiple times throughout the year, indicating a continuous improvement in order conversion, project advancement, and capacity utilization [6][29] Group 4 - Market sentiment towards WuXi AppTec is complex, with a significant portion of profit growth attributed to non-recurring gains from asset disposals, leading to a cautious market outlook despite strong operational performance [7][30] - The market's valuation reflects skepticism not about 2025 performance but about the sustainability of growth beyond 2027 [7][30] Group 5 - Concerns regarding the future growth of TIDES and geopolitical risks are central to market pricing, indicating a focus on long-term growth potential rather than immediate performance [9][32] - The demand for TIDES products remains strong, with supply chain share increasing, suggesting that the challenges are more about supply capacity than demand saturation [11][34] Group 6 - WuXi AppTec's growth is characterized by a platform-based expansion rather than reliance on a single segment, with significant performance in small molecule D&M business [15][38] - The company has improved operational efficiency and capacity utilization without significant capital investment, enhancing its competitive position in the global pharmaceutical outsourcing industry [17][40] Group 7 - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand area, emphasizing the importance of time in meeting customer needs [19][41] - This acquisition reflects a broader trend of consolidation in the industry, where leading companies are increasingly focused on embedding themselves deeper into the global innovative drug supply chain [21][43] Group 8 - The current rebound in the CXO sector appears to be driven by sentiment and expectations rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [22][44] - The ongoing structural changes in the industry suggest that companies that have successfully adjusted their order and capability structures may see their value reassessed in the future [22][45]

Core Viewpoint - The China Securities Medical Index (399989) closed at 7161.62 points, up 0.6%, with a trading volume of 19.192 billion yuan and a turnover rate of 1.97% on February 9 [1] Group 1: Index Performance - On the same day, 37 of the index's constituent stocks rose, with Sanbo Brain Science leading with a 5.32% increase, while 12 stocks declined, with Aier Eye Hospital falling by 2.98% [1] - The top ten constituent stocks of the China Securities Medical Index are primarily in the pharmaceutical and medical sectors, with WuXi AppTec holding the highest weight at 10.03% [1] Group 2: Stock Details - The top ten stocks include: - WuXi AppTec: Weight 10.03%, Latest Price 98.70, Market Cap 294.97 billion yuan [1] - Mindray Medical: Weight 9.12%, Latest Price 189.17, Market Cap 229.36 billion yuan [1] - United Imaging Healthcare: Weight 7.49%, Latest Price 128.92, Market Cap 106.25 billion yuan [1] - Aier Medical: Weight 6.04%, Latest Price 10.74, Market Cap 100.16 billion yuan [1] - Other notable stocks include Tigermed, Kanglong Chemical, and Yuyue Medical, all within the medical and pharmaceutical industry [1] Group 3: Capital Flow - The net outflow of main funds from the index's constituent stocks totaled 205 million yuan, while retail investors saw a net inflow of 1.51 billion yuan [1] - Detailed capital flow indicates that major stocks like WuXi AppTec and Mindray Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant discrepancies between H-shares and A-shares [1] Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 831.03%, with H-share priced at 0.290 HKD and A-share at 2.25 CNY [1] - Zhejiang Shibao (01057) follows with a premium rate of 347.33%, H-share at 5.810 HKD and A-share at 21.7 CNY [1] - Sinopec Oilfield Service (01033) ranks third with a premium rate of 304.44%, H-share at 0.900 HKD and A-share at 3.04 CNY [1] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -13.97%, with H-share priced at 513.500 HKD and A-share at 368.82 CNY [1] - China Merchants Bank (03968) has a premium rate of -3.80%, H-share at 49.220 HKD and A-share at 39.53 CNY [1] - Heng Rui Medicine (01276) shows a minimal premium rate of -0.35%, with H-share at 69.050 HKD and A-share at 57.45 CNY [1] Group 3: Top Deviation Values - Sinopec Oilfield Service (01033) leads in deviation value at 26.29%, indicating a significant difference from its average premium rate [1] - Beijing Jingcheng Machinery Electric (00187) has a deviation value of 22.66% [1] - Longpan Technology (02465) ranks third with a deviation value of 19.24% [1] Group 4: Bottom Deviation Values - Junda Co., Ltd. (02865) has the lowest deviation value at -66.46%, indicating a substantial drop from its average premium rate [1] - Zhejiang Shibao (01057) follows with a deviation value of -42.67% [1] - Yangtze Optical Fibre and Cable (06869) shows a deviation value of -33.26% [1]

Core Viewpoint - The recent rebound in the CXO sector is not indicative of a comprehensive recovery but rather a reaction to easily confirmable short-term improvements, particularly among domestic demand-driven CRO and experimental service companies, while leading CDMO companies focused on external demand have underperformed [3][4][5]. Market Dynamics - The market is currently trading based on short-term rebounds rather than a long-term recovery in the CXO industry, with a notable divergence in performance between domestic-focused companies and those reliant on global demand [4][5]. - Despite an overall positive sentiment in the industry, caution remains regarding CDMO companies, which are facing complex pricing environments and geopolitical uncertainties that could impact long-term growth [5][12]. Financial Performance - WuXi AppTec's 2025 performance forecast indicates a revenue of approximately 454.56 billion RMB, a year-on-year increase of about 15.84%, and a net profit of around 191.51 billion RMB, reflecting a significant growth of 102.65% [7]. - The company's revenue growth trajectory has shown consistent improvement throughout the year, with a core business revenue increase of approximately 21.40%, indicating enhanced growth momentum post-divestiture of certain business segments [9][10]. Market Sentiment and Valuation - The market's cautious stance towards CDMO companies is driven by uncertainties regarding future growth, particularly in relation to geopolitical risks and the sustainability of demand for emerging business lines like TIDES [12][13]. - The valuation of CDMO companies reflects a conservative outlook on long-term growth potential rather than immediate revenue uncertainties, leading to a disconnect between fundamental recovery and stock price performance [10][28]. Structural Changes in the Industry - The growth in WuXi AppTec's small molecule D&M business is attributed to an expansion in order structure and capabilities, moving beyond traditional roles to encompass more complex production processes [20][22]. - The acquisition of Dongyao Pharmaceutical by WuXi AppTec highlights a strategic move to secure capacity in a high-demand sector, emphasizing the importance of time as a critical resource in the competitive landscape [24][26]. Conclusion - The current rebound in the CXO sector appears to be driven by emotional and anticipatory factors rather than a full reassessment of long-term industry value, with a clear distinction between domestic and external demand dynamics [28][29].

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]